The NMPA has approved Trodelvy for unresectable LA or metastatic TNBC in adult patients with ≥2 prior systemic therapies & for metastatic disease. The product is expected to be available in China in Q4’22
The P-IIb (EVER-132-001) study met its 1EPs & showed a 38.8% ORR. The results were consistent with those from the P-III (ASCENT) study along with similar efficacy & safety in the Chinese population
Trodelvy is being developed for TNBC & metastatic UC populations along with multiple tumors including HR+/HER2- metastatic breast cancer, m-NSCLC & SCLC, HNC & EC. Following the license agreement with Gilead, Everest gets an exclusive rights to develop, register & commercialize Trodelvy for cancer indications in Greater China & other countries
Ref: PR Newswire | Image: Everest Medicine
